Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL
DLBCL is the most common lymphoma with high tumor heterogeneity. Treatment refractoriness and relapse from R-CHOP therapy in patients remain a clinical problem. Activation of the non-canonical NF-κB pathway is associated with R-CHOP resistance. However, downstream targets of non-canonical NF-κB medi...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
其他作者: | |
格式: | Article |
語言: | English |
出版: |
2023
|
主題: | |
在線閱讀: | https://hdl.handle.net/10356/164468 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|